Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | SNCA | P37840 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27607313 | 0.88 | NOX1 (0.55) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL5362784 | 0.85 | NOX1 (0.52) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL293434 | 0.85 | ALOX5 (0.54) | NOX1MAPTGAAALOX15SNCA | |
| Benzene SCHEMBL28125613 | 0.85 | ALOX5 (0.54) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL7162110 | 0.84 | NOX1 (0.50) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL31657639 | 0.84 | NOX1 (0.55) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL1719765 | 0.84 | NOX1 (0.55) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL547518 | 0.83 | NOX1 (0.48) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL1509785 | 0.82 | NOX1 (0.49) | NOX1MAPTGAAALOX15SNCA | |
| SCHEMBL2803233 | 0.81 | GAA (0.47) | NOX1MAPTGAAALOX15SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777481-A1 | USE OF N-SUBSTITUTED PHENOTHIAZINES | BAYER AG (DE) | 1997-06-11 | — | — | EP | claimed |
| WO-1996005837-A1 | USE OF N-SUBSTITUTED PHENOTHIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-29 | — | — | WO | claimed |
| EP-2351724-B1 | PROCESS FOR PRODUCING p-DICHLOROBENZENE | TOSOH CORP (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1317454-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2295054-A1 | Ice inhibitors for the treatment of autoinflammatory diseases | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1778221-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005117846-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267101-A1 | Interleukin-1 beta converting enzyme inhibitor: 3-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-3-formylpropionic acid or 4-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-5-ethoxy-2-tetrahydrofuranone; autoinflammatory diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-12-01 | — | — | US | disclosed |
| US-6800619-B2 | UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-05 | — | — | US | disclosed |
| WO-2004082826-A2 | CATALYST COMPOSITION AND METHOD FOR CHLORINATING AROMATIC COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040048797-A1 | Regulation of TNF-alpha | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-11 | — | — | US | disclosed |
| WO-2003088917-A2 | REGULATION OF TNF-ALPHA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1317454-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020058630-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-16 | — | — | US | disclosed |
| WO-2002022611-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-0126669-B1 | N-SUBSTITUTED PHENOTHIAZINE DERIVATIVE AS A CATALYST FOR THE NUCLEAR CHLORINATION OF AROMATIC HYDROCARBONS | ELF ATOCHEM S.A. (FR) | 1986-08-27 | — | — | EP | disclosed |
| EP-0126669-A1 | N-substituted phenothiazine derivative as a catalyst for the nuclear chlorination of aromatic hydrocarbons | ELF ATOCHEM S.A. (FR) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058630-A1 | Caspase inhibitors and uses thereof | CASP2, CASP3, CASP7 | NOX1 2272/4885MAPT 4537/4885GAA 2738/4885 |
| US-20040048797-A1 | Regulation of TNF-alpha | TNF, TNFRSF1A, TNFRSF9 | NOX1 257/4885MAPT 3010/4885GAA 186/4885 |
| US-20050267101-A1 | Interleukin-1 beta converting enzyme inhibitor: 3-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-3-formylpropionic acid or 4-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-5-ethoxy-2-tetrahydrofuranone; autoinflammatory diseases | IL1B, IL1A, NFKBIA | NOX1 1286/4885MAPT 583/4885GAA 1438/4885 |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | UACA, SSB, NFKBIA | NOX1 2574/4885MAPT 30/4885GAA 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.